The Top Line

    The Top Line

    Fierce Life Sciences

    Track List

    Nr Play Info/Play Duration Track/Download
    1 INFO/audio 0:39:41 Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more
    2 INFO/audio 0:32:45 Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
    3 INFO/audio 0:15:06 What can we learn from 2024’s biotech IPOs?
    4 INFO/audio 0:12:30 Meet 2024’s fiercest women in life sciences
    5 INFO/audio 0:15:29 Misconduct and the future of neurodegenerative disease research
    6 INFO/audio 0:11:51 Dig into this year’s Fierce Biotech Graveyard, layoff numbers
    7 INFO/audio 0:16:34 Drug pricing and the 2024 presidential election
    8 INFO/audio 0:18:15 Discover Turbine’s way to build avatars true to patient biology [Sponsored]
    9 INFO/audio 0:20:13 The pulse of the medtech industry
    10 INFO/audio 0:32:49 Where are they now? Catching up with past Fierce 15 honorees
    11 INFO/audio 0:23:55 Revolutionizing gene therapy logistics with Cryoport's Elite solution [Sponsored]
    12 INFO/audio 0:40:29 A revival in neuro therapeutics
    13 INFO/audio 0:20:02 Breaking down BIOSECURE—Industry implications and what comes next
    14 INFO/audio 0:23:17 ESMO, WCLC lung cancer data spark hope—and debate
    15 INFO/audio 0:08:23 Recapping Digital Pharma East 2024
    16 INFO/audio 0:07:24 A closer look at the Fierce 50
    17 INFO/audio 0:17:10 A look at flu vaccine manufacturing and supply in the post-pandemic era
    18 INFO/audio 0:20:46 Driving flu vaccine uptake in the post-pandemic era
    19 INFO/audio 0:13:42 The Crucial Role of HEK293 DNA Quantification in Biotherapeutics [Sponsored by Bio-Rad Laboratories]
    20 INFO/audio 0:25:15 What Chevron’s overturn means for biopharma
    21 INFO/audio 0:24:41 The TROP2 race for supremacy
    22 INFO/audio 0:11:17 A closer look at Fierce Biotech's Fierce 15
    23 INFO/audio 0:26:38 What 'The Next Berlin Patient' and a PrEP’s 100% efficacy mean for HIV drug development
    24 INFO/audio 0:10:02 Fierce 15: Where are they now?
    25 INFO/audio 0:17:18 Former FTC director weighs in on Novo's $16.5B deal with Catalent
    26 INFO/audio 0:13:45 Find out what to expect from the PDA/FDA Joint Regulatory Conference (Sponsored by Parenteral Drug Association)
    27 INFO/audio 0:10:47 A look at Big Pharma’s top-paid CEOs
    28 INFO/audio 0:15:02 The best biopharma M&A deals
    29 INFO/audio 0:17:54 A closer look at 'friend-shoring' and the drug shortage challenge
    30 INFO/audio 0:13:35 Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth
    31 INFO/audio 0:09:35 A look at the top 10 pharma drug ad spenders
    32 INFO/audio 0:06:31 A cell therapy reckoning
    33 INFO/audio 0:39:37 Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)
    34 INFO/audio 0:17:00 [Sponsored] Opportunities & Challenges of Digital Pathology Adoption in CDx Development
    35 INFO/audio 0:15:11 [Sponsored] Unlocking health equity: The promise of digital health technologies
    36 INFO/audio 0:31:23 Advancements in cell & gene therapy manufacturing (Part II)
    37 INFO/audio 0:29:15 Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
    38 INFO/audio 0:18:07 A closer look at 2023's top biopharma deals and what lies ahead
    39 INFO/audio 0:10:28 A look at pharma revenue rankings
    40 INFO/audio 0:14:30 Winning formulas for the best biotech and drug names
    41 INFO/audio 0:11:34 [Sponsored] What does the future of specialist distribution look like?
    42 INFO/audio 0:17:47 Deep dive: Biopharma layoffs in Q1
    43 INFO/audio 0:14:12 The unrecognized threat of PAD
    44 INFO/audio 0:18:55 The top money raisers in biotech
    45 INFO/audio 0:18:28 A closer look at European biotech investment in 2024
    46 INFO/audio 0:14:45 Inclusivity in psoriasis trials with Takeda
    47 INFO/audio 0:16:20 Fierce Medtech's Fierce 15
    48 INFO/audio 0:16:02 [Sponsored] A Person-Centered Approach to Achieving Long-Term Success
    49 INFO/audio 0:33:57 CAR-T boxed warnings: What comes next?
    50 INFO/audio 0:23:16 Breaking down Eli Lilly’s ESG formula
    51 INFO/audio 0:25:44 Gene editing's next act
    52 INFO/audio 0:11:06 The most anticipated drug launches of 2024